IL296080B2 - Method for treating cancer - Google Patents

Method for treating cancer

Info

Publication number
IL296080B2
IL296080B2 IL296080A IL29608022A IL296080B2 IL 296080 B2 IL296080 B2 IL 296080B2 IL 296080 A IL296080 A IL 296080A IL 29608022 A IL29608022 A IL 29608022A IL 296080 B2 IL296080 B2 IL 296080B2
Authority
IL
Israel
Prior art keywords
amount
compound
formulation
pharmaceutical formulation
solid pharmaceutical
Prior art date
Application number
IL296080A
Other languages
English (en)
Hebrew (he)
Other versions
IL296080A (en
IL296080B1 (en
Original Assignee
Eisai R&D Man Co Ltd
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Epizyme Inc filed Critical Eisai R&D Man Co Ltd
Publication of IL296080A publication Critical patent/IL296080A/en
Publication of IL296080B1 publication Critical patent/IL296080B1/en
Publication of IL296080B2 publication Critical patent/IL296080B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
IL296080A 2014-11-17 2015-11-17 Method for treating cancer IL296080B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462080985P 2014-11-17 2014-11-17
US201562166572P 2015-05-26 2015-05-26
US201562251903P 2015-11-06 2015-11-06
PCT/US2015/061194 WO2016081523A1 (en) 2014-11-17 2015-11-17 Method for treating cancer

Publications (3)

Publication Number Publication Date
IL296080A IL296080A (en) 2022-11-01
IL296080B1 IL296080B1 (en) 2023-08-01
IL296080B2 true IL296080B2 (en) 2023-12-01

Family

ID=56014476

Family Applications (4)

Application Number Title Priority Date Filing Date
IL296080A IL296080B2 (en) 2014-11-17 2015-11-17 Method for treating cancer
IL252182A IL252182B2 (en) 2014-11-17 2017-05-09 Cancer treatment methods
IL304252A IL304252B1 (en) 2014-11-17 2023-07-04 Cancer treatment methods
IL323396A IL323396A (en) 2014-11-17 2025-09-16 Cancer treatment methods

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL252182A IL252182B2 (en) 2014-11-17 2017-05-09 Cancer treatment methods
IL304252A IL304252B1 (en) 2014-11-17 2023-07-04 Cancer treatment methods
IL323396A IL323396A (en) 2014-11-17 2025-09-16 Cancer treatment methods

Country Status (21)

Country Link
US (3) US10786511B2 (OSRAM)
EP (2) EP3220916B1 (OSRAM)
JP (3) JP6829684B2 (OSRAM)
KR (3) KR20240035908A (OSRAM)
CN (2) CN107249591B (OSRAM)
AU (3) AU2015350108B2 (OSRAM)
BR (1) BR112017010166A2 (OSRAM)
CA (1) CA2967664A1 (OSRAM)
DK (1) DK3220916T3 (OSRAM)
EA (1) EA201791095A1 (OSRAM)
ES (1) ES2947819T3 (OSRAM)
FI (1) FI3220916T3 (OSRAM)
HU (1) HUE062159T2 (OSRAM)
IL (4) IL296080B2 (OSRAM)
LT (1) LT3220916T (OSRAM)
MX (2) MX383484B (OSRAM)
PL (1) PL3220916T3 (OSRAM)
PT (1) PT3220916T (OSRAM)
SG (1) SG11201703806XA (OSRAM)
SI (1) SI3220916T1 (OSRAM)
WO (1) WO2016081523A1 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
AU2013331368A1 (en) 2012-10-15 2015-04-30 Epizyme, Inc. Methods of treating cancer
ES2863996T3 (es) 2013-12-06 2021-10-13 Epizyme Inc Terapia de combinación para el tratamiento del cáncer
JP6779793B2 (ja) 2014-06-17 2020-11-04 エピザイム，インコーポレイティド リンパ腫を治療するためのｅｚｈ２阻害剤
HUE062159T2 (hu) 2014-11-17 2023-10-28 Epizyme Inc Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal
MX391720B (es) 2015-04-20 2025-03-21 Epizyme Inc Terapia combinada para tratar cáncer.
MX387885B (es) 2015-06-10 2025-03-19 Epizyme Inc Inhibidores de ezh2 para tratar linfomas.
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
EP3407978A4 (en) 2016-01-29 2020-01-15 Epizyme Inc POLYTHERAPY FOR THE TREATMENT OF CANCER
EP3464643A4 (en) 2016-06-01 2020-04-01 Epizyme Inc USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER
MA45406A (fr) 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer
AU2018210099A1 (en) 2017-01-19 2019-08-15 Daiichi Sankyo Company, Limited Pharmaceutical composition used for treatment of HTLV-1-associated myelopathy
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
CA3074720A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. Combination therapy for treating cancer
IL294108A (en) * 2019-12-20 2022-08-01 Epizyme Inc Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer
JP7628876B2 (ja) 2021-04-23 2025-02-12 日立Astemo株式会社 情報処理装置、情報処理方法、プログラムおよび記憶媒体
WO2023159124A2 (en) * 2022-02-17 2023-08-24 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients
EP4514391A1 (en) 2022-04-27 2025-03-05 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119052D0 (en) 1991-09-06 1991-10-23 Boots Co Plc Pharmaceutical compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070026064A1 (en) * 2005-07-29 2007-02-01 Yoder Steven L Pharmaceutical dosage forms having watermark-type identification and authentication inditia
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
RU2765155C2 (ru) * 2010-09-10 2022-01-26 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012097222A1 (en) * 2011-01-14 2012-07-19 Bristol-Myers Squibb Company High drug load tablet formulation of brivanib alaninate
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
EP3536314A1 (en) * 2012-03-12 2019-09-11 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
EP2836216B1 (en) * 2012-04-13 2022-06-08 Epizyme, Inc. Combination therapy for treating cancer
SG10201608577RA (en) * 2012-04-13 2016-12-29 Epizyme Inc Salt form of a human hi stone methyltransf erase ezh2 inhibitor
NZ706738A (en) 2012-10-15 2018-10-26 Epizyme Inc Substituted benzene compounds
AU2013331368A1 (en) * 2012-10-15 2015-04-30 Epizyme, Inc. Methods of treating cancer
EP2934531A4 (en) 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
CA2894222A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
WO2014100646A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
WO2014172044A1 (en) 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
EP3022184B1 (en) 2013-07-19 2017-09-27 Epizyme, Inc. Substituted benzene compounds
LT3057962T (lt) * 2013-10-16 2023-12-11 Epizyme, Inc. Hidrochlorido druskos forma, skirta ezh2 inhibavimui
WO2015058125A1 (en) 2013-10-18 2015-04-23 Epizyme, Inc. Method of treating cancer
ES2863996T3 (es) 2013-12-06 2021-10-13 Epizyme Inc Terapia de combinación para el tratamiento del cáncer
JP6779793B2 (ja) * 2014-06-17 2020-11-04 エピザイム，インコーポレイティド リンパ腫を治療するためのｅｚｈ２阻害剤
US20170217941A1 (en) 2014-06-25 2017-08-03 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
KR102397720B1 (ko) 2014-10-16 2022-05-13 에피자임, 인코포레이티드 암을 치료하기 위한 방법
HUE062159T2 (hu) * 2014-11-17 2023-10-28 Epizyme Inc Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal
MX387885B (es) * 2015-06-10 2025-03-19 Epizyme Inc Inhibidores de ezh2 para tratar linfomas.
MA45406A (fr) * 2016-06-17 2019-04-24 Epizyme Inc Inhibiteurs d'ezh2 pour traiter le cancer

Also Published As

Publication number Publication date
EP3220916A4 (en) 2018-07-11
JP2023062189A (ja) 2023-05-02
AU2015350108A1 (en) 2017-05-25
KR20170103768A (ko) 2017-09-13
PT3220916T (pt) 2023-06-26
BR112017010166A2 (en) 2018-02-14
LT3220916T (lt) 2023-07-25
IL296080A (en) 2022-11-01
HUE062159T2 (hu) 2023-10-28
JP2017537899A (ja) 2017-12-21
WO2016081523A1 (en) 2016-05-26
MX2017006089A (es) 2017-12-11
US20250064822A1 (en) 2025-02-27
MX383484B (es) 2025-03-11
NZ731696A (en) 2024-03-22
AU2015350108B2 (en) 2021-04-08
US20210060030A1 (en) 2021-03-04
KR20240035908A (ko) 2024-03-18
CN107249591B (zh) 2024-01-30
US12168014B2 (en) 2024-12-17
SG11201703806XA (en) 2017-06-29
IL252182A0 (en) 2017-07-31
IL252182B2 (en) 2023-02-01
CA2967664A1 (en) 2016-05-26
US20170360797A1 (en) 2017-12-21
KR20210156840A (ko) 2021-12-27
EP3220916B1 (en) 2023-04-19
NZ768247A (en) 2024-05-31
AU2024201171A1 (en) 2024-03-14
IL296080B1 (en) 2023-08-01
CN116650500A (zh) 2023-08-29
AU2021204706B2 (en) 2023-11-23
AU2021204706A1 (en) 2021-07-29
IL252182B (en) 2022-10-01
JP6829684B2 (ja) 2021-02-10
EA201791095A1 (ru) 2017-10-31
PL3220916T3 (pl) 2023-08-14
JP7485810B2 (ja) 2024-05-16
SI3220916T1 (sl) 2023-09-29
CN107249591A (zh) 2017-10-13
KR102338802B1 (ko) 2021-12-14
IL323396A (en) 2025-11-01
JP2021073241A (ja) 2021-05-13
IL304252B1 (en) 2025-11-01
IL304252A (en) 2023-09-01
MX2021006734A (es) 2021-07-02
KR102644844B1 (ko) 2024-03-07
DK3220916T3 (da) 2023-06-26
ES2947819T3 (es) 2023-08-21
EP3220916A1 (en) 2017-09-27
EP4272742A1 (en) 2023-11-08
FI3220916T3 (fi) 2023-06-19
US10786511B2 (en) 2020-09-29

Similar Documents

Publication Publication Date Title
AU2021204706B2 (en) Method for treating cancer
US11642349B2 (en) Method for treating cancer
IL257442B2 (en) Process for preparing parp inhibitor, crystalline forms and their uses
HK40103478A (en) Epz-6438 for use in a method for treating cancer
EA048689B1 (ru) Твердый фармацевтический состав для лечения рака
HK40000800B (zh) 共晶体